Ionis to Present Inotersen NEURO-TTR Phase 3 Study Results at 1st European ATTR Amyloidosis Meeting

Company to host webcast conference call on Thursday, November 2 at 7:00 a.m. Eastern Time CARLSBAD, Calif., Nov. 1, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Thursday, November 2 at 7:00 a.m. Eastern Time to review data from the Phase 3 NEURO-TTR study presented at the European ATTR Amyloidosis Meeting in Paris, France.

The release as fetched from its publisher. ionis.com ↗